

# PCH Neuro Oncology Tumor Board 2024

## PCH Neuro Oncology Tumor Board 2024 - 8/21/2024

August 21, 2024 – 12:00 PM  
Online

### Overall Activity Objectives:

- 1 To review histological and molecular CNS tumor diagnoses in children
- 2 Implement evidence-based guidelines for treatment of pediatric CNS tumors
- 3 Incorporate into practice knowledge of genetic nuances to diagnose and treat pediatric brain tumors
- 4 Employ appropriate diagnostic strategies for suspected neuro oncologic conditions
- 5 Utilize appropriate evidence-based treatment strategies for neuro oncologic diagnoses

### Session Objectives:

- 1 To review histological and molecular CNS tumor diagnoses in children
- 2 Implement evidence-based guidelines for treatment of pediatric CNS tumors
- 3 Incorporate into practice knowledge of genetic nuances to diagnose and treat pediatric brain tumors
- 4 Employ appropriate diagnostic strategies for suspected neuro oncologic conditions
- 5 Utilize appropriate evidence-based treatment strategies for neuro oncologic diagnoses

### Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Phoenix Children's Hospital The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

| Name of individual  | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s)   |
|---------------------|-------------------------------|---|
| Lindsey Hoffman, DO | Activity Director, Faculty    | Honoraria-Bayer (Any division) (Relationship has ended) Honoraria-Novartis Corporation Pharmaceuticals (Relationship has ended) Consulting Fee-Lilly (Any division) (Relationship |

|                 |         |                                  |
|-----------------|---------|----------------------------------|
|                 |         | has ended) - 06/12/2024          |
| Ross Mangum, MD | Faculty | Nothing to disclose - 05/24/2024 |



THE UNIVERSITY OF ARIZONA

College of Medicine

Tucson